Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Bialer Meir

Researchers

 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Odi R, Bibi D, Shusterman B, Erenburg N, Shaul C, Supuran CT, et al. Synthesis and enantioselective pharmacokinetic/ pharmacodynamic analysis of new CNS-active sulfamoylphenyl carbamate derivatives. Int J Mol Sci 2021;22(7).

(2) Franco V, Bialer M, Perucca E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology 2021;185.

(3) Odi R, Franco V, Perucca E, Bialer M. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. Epilepsia 2021;62(2):285-302.

(4) Franco V, Gershkovich P, Perucca E, Bialer M. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clin Pharmacokinet 2020;59(12):1493-1500.

(5) Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia 2020;61(11):2340-2364.

(6) Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia 2020;61(11):2365-2385.

(7) Bialer M, Perucca E. Response: Cannabidiol antiseizure activity and its interactions with clobazam: “It’s déjà vu all over again” Yogi Berra. Epilepsia 2020;61(8):1793-1794.

(8) Perucca E, Bialer M. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs 2020;34(8):795-800.

(9) Odi R, Bibi D, Wager T, Bialer M. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs—From phenobarbital to cenobamate and beyond. Epilepsia 2020;61(8):1543-1552.

(10) Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia 2020;61(6):1082-1089.

(11) Bibi D, Bialer M. Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs—A CNS-active stereoisomer of SPD. Epilepsia 2020;61(1):149-156.

(12) Bialer M, Cross H, Hedrich UBS, Lagae L, Lerche H, Loddenkemper T. Novel treatment approaches and pediatric research networks in status epilepticus. Epilepsy Behav 2019;101.

(13) Lin YL, Bialer M, Cabrera RM, Finnell RH, Wlodarczyk BJ. Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. Birth Defects Res 2019;111(14):1013-1023.

(14) Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV). Epilepsy Res 2019;153:66-67.

(15) Haines KM, Matson LM, Dunn EN, Ardinger CE, Lee-Stubbs R, Bibi D, et al. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent–induced seizures in pediatric rats. Epilepsia 2019;60(2):315-321.

(16) Bibi D, Shusterman B, Nocentini A, Supuran CT, Bialer M. Stereoselective pharmacokinetic and pharmacodynamic analysis of a CNS-active sulphamoylphenyl carbamate derivative. J Enzyme Inhib Med Chem 2019;34(1):1078-1082.

(17) Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia 2018;59(10):1811-1841.

(18) Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia 2018;59(10):1842-1866.

(19) Kudin AP, Mawasi H, Eisenkraft A, Elger CE, Bialer M, Kunz WS. Mitochondrial liver toxicity of valproic acid and its acid derivatives is related to inhibition of α-lipoamide dehydrogenase. Int J Mol Sci 2017;18(9).

(20) Bibi D, Mawasi H, Nocentini A, Supuran CT, Wlodarczyk B, Finnell RH, et al. Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide. Neurochem Res 2017;42(7):1972-1982.

(21) Weiser M, Levi L, Levine SZ, Bialer M, Shekh-Ahmad T, Matei V, et al. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar Disord 2017;19(4):285-294.

(22) Kaufmann D, West PJ, Smith MD, Yagen B, Bialer M, Devor M, et al. sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. Pharmacol Res 2017;117:129-139.

(23) Shaul C, Blotnick S, Muszkat M, Bialer M, Caraco Y. Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. Mol Diagn Ther 2017;21(1):75-83.

(24) Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia 2017;58(2):181-221.

(25) Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, et al. Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII). Epilepsy Res 2017;130:27-36.

(26) Kaufmann D, Bates EA, Yagen B, Bialer M, Saunders GH, Wilcox K, et al. Sec -Butylpropylacetamide (SPD) has antimigraine properties. Cephalalgia 2016;36(10):924-935.

(27) Mawasi H, Bibi D, Shekh-Ahmad T, Shaul C, Blotnik S, Bialer M. Pharmacokinetic-pharmacodynamic correlation and brain penetration of sec-butylpropylacetamide, a new CNS drug possessing unique activity against status epilepticus. Mol Pharm 2016;13(7):2492-2496.

(28) Mawasi H, Bibi D, Bialer M. Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. Bioorg Med Chem 2016;24(18):4246-4253.

(29) Wlodarczyk BJ, Ogle K, Lin LY, Bialer M, Finnell RH. Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord 2015;17(6):615-625.

(30) Korczyn AD, Schachter SC, Amlerova J, Bialer M, van Emde Boas W, Brázdil M, et al. Third International Congress on Epilepsy, Brain and Mind: Part 1. Epilepsy Behav 2015;50:116-137.

(31) Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav 2015;49:298-302.

(32) Mawasi H, Shekh-Ahmad T, Finnell RH, Wlodarczyk BJ, Bialer M. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide - Amide derivatives of valproic acid. Epilepsy Behav 2015;46:72-78.

(33) Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res 2015;111:85-141.

(34) Shekh-Ahmad T, Hen N, Yagen B, McDonough JH, Finnell RH, Wlodarczyk BJ, et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 2014;55(2):353-361.

(35) Karalis V, MacHeras P, Bialer M. Generic products of antiepileptic drugs: A perspective on bioequivalence, bioavailability, and formulation switches using monte carlo simulations. CNS Drugs 2014;28(1):69-77.

(36) Shekh-Ahmad T, Mawasi H, McDonough JH, Finnell RH, Wlodarczyk BJ, Yavin E, et al. Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. Epilepsia 2014;55(12):1944-1952.

(37) Bar-Klein G, Swissa E, Kamintsky L, Shekh-Ahmad T, Saar-Ashkenazy R, Hubary Y, et al. Sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia 2014;55(12):1953-1958.

(38) Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia 2013;54(SUPPL. 6):99-102.

(39) Neuman MG, Nanau RM, Shekh-Ahmad T, Yagen B, Bialer M. Valproic acid derivatives signal for apoptosis and repair in vitro. Clin Biochem 2013;46(15):1532-1537.

(40) Karalis V, Bialer M, Macheras P. Quantitative assessment of the switchability of generic products. Eur J Pharm Sci 2013;50(3-4):476-483.

(41) Mareš P, Kubová H, Hen N, Yagen B, Bialer M. Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. Epilepsy Res 2013;106(1-2):64-73.

(42) Hen N, Shekh-Ahmad T, Yagen B, McDonough JH, Finnell RH, Wlodarczyk B, et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec -butylpropylacetamide (SPD), a new CNS-Active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013;56(16):6467-6477.

(43) Bialer M, Shekh-Ahmad T, Braun TL, Halvorsen MB. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 2013;54(8):1444-1452.

(44) Elger C, Bialer M, Falcão A, Vaz-Da-Silva M, Nunes T, Almeida L, et al. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia 2013;54(8):1453-1461.

(45) Onishi Y, Okada A, Noyori H, Okamura A, Hen N, Yagen B, et al. Teratology study of amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide in NMRI mice. Birth Defects Res Part B Dev Reprod Toxicol 2013;98(4):318-327.

(46) Modi HR, Basselin M, Taha AY, Li LO, Coleman RA, Bialer M, et al. Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: A potential drug for bipolar disorder. Biochim Biophys Acta Mol Cell Biol Lipids 2013;1831(4):880-886.

(47) Pouliot W, Bialer M, Hen N, Shekh-Ahmad T, Kaufmann D, Yagen B, et al. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013;231:145-156.

(48) Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013;103(1):2-30.

(49) Smith P, Bialer M. The borderland of epilepsy: Chairs' Symposium, 10th European Congress on Epileptology, London--October 1, 2012. Introduction. Epilepsia 2012;53 Suppl 7:1-2.

(50) Bialer M. Comments on the working group's 2012 review of the Program. Epilepsia 2012;53(10):1844-1846.

(51) Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012;64(10):887-895.

(52) Bialer M, Soares-Da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 2012;53(6):935-946.

(53) Bejarano-Achache I, Levy L, Mlynarsky L, Bialer M, Muszkat M, Caraco Y. Effects of CYP4F2 Polymorphism on Response to Warfarin During Induction Phase: A Prospective, Open-Label, Observational Cohort Study. Clin Ther 2012;34(4):811-823.

(54) Hen N, Bialer M, Yagen B. Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. J Med Chem 2012;55(6):2835-2845.

(55) Shekh-Ahmad T, Bialer M, Yavin E. Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue. Epilepsy Res 2012;98(2-3):238-246.

(56) Bialer M. How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)? Epilepsia 2012;53 Suppl 8:3-11.

(57) Bialer M, Smith PE. Special issue: Phenobarbital: the Centenary - 10th European Congress on Epileptology, London - October 1, 2012. Introduction. Epilepsia 2012;53 Suppl 8:1-2.

(58) Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 2012;53 Suppl 7:26-33.

(59) Chang P, Orabi B, Deranieh RM, Dham M, Hoeller O, Shimshoni JA, et al. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. DNM Dis Models Mech 2012;5(1):115-124.

(60) White HS, Alex AB, Pollock A, Hen N, Shekh-Ahmad T, Wilcox KS, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012;53(1):134-146.

(61) Pessah N, Yagen B, Hen N, Shimshoni JA, Wlodarczyk B, Finnell RH, et al. Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid. Epilepsy Behav 2011;22(3):461-468.

(62) Lambrecht LJ, Shekh-Ahmad T, Todd WM, Halvorsen MB, Bialer M. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia 2011;52(10):1877-1883.

(63) Hen N, Bialer M, Yagen B, Maresca A, Aggarwal M, Robbins AH, et al. Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. J Med Chem 2011;54(11):3977-3981.

(64) Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92(2-3):89-124.

(65) Pessah N, Kaufmann D, Yagen B, Hen N, Wlodarczyk B, Finnell RH, et al. Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. Epilepsia 2010;51(10):1944-1953.

(66) Bialer M, Midha KK. Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeability. Epilepsia 2010;51(6):941-950.

(67) Kaufmann D, Yagen B, Minert A, Wlodarczyk B, Finnell RH, Schurig V, et al. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology 2010;58(8):1228-1236.

(68) Hen N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. J Med Chem 2010;53(10):4177-4186.

(69) Shimshoni JA, Yagen B, Wlodarczyk B, Finnell RH, Schurig V, Bialer M. Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): A chiral stereoisomer of valproic acid urea derivative. Epilepsia 2010;51(3):323-332.

(70) Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010;9(1):68-82.

(71) Bialer M. Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus. Epilepsia 2009;50:44-48.

(72) Kaufmann D, Bialer M, Shimshoni JA, Devor M, Yagen B. Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. J Med Chem 2009;52(22):7236-7248.

(73) Okada A, Noyori H, Yagen B, Shimshoni JA, Bialer M, Fujiwara M. Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice. Birth Defects Res Part B Dev Reprod Toxicol 2009;86(5):394-401.

(74) Zannikos P, Novak G, Yao C, Verhaeghe T, Franc MA, Solanki B, et al. Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. Epilepsia 2009;50(8):1850-1859.

(75) Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine Acetate. The Treatment of Epilepsy: Third Edition; 2009. p. 485-498.

(76) Pessah N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. α-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J Med Chem 2009;52(8):2233-2242.

(77) Elger C, Bialer M. Epilepsia: Foreword. Epilepsia 2009;50(SUPPL. 4):1.

(78) Shimshoni JA, Dalton EC, Watson P, Yagen B, Bialer M, Harwood AJ. Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology. Neuropharmacology 2009;56(4):831-837.

(79) Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83(1):1-43.

(80) Okada A, Onishi Y, Yagen B, Shimshoni JA, Kaufmann D, Bialer M, et al. Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: Evaluation of the teratogenic effects of its amide derivatives in NMRI mice. Birth Defects Res Part A Clin Mol Teratol 2008;82(9):610-621.

(81) Shimshoni JA, Yagen B, Pessah N, Wlodarczyk B, Finnell RH, Bialer M. Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: A potential for a second generation drug to valproic acid. Epilepsia 2008;49(7):1202-1212.

(82) Shimshoni JA, Bialer M, Yagen B. Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives. Bioorg Med Chem 2008;16(11):6297-6305.

(83) Kaufmann D, Yagen B, Minert A, Tal M, Devor M, Bialer M. Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. Neuropharmacology 2008;54(4):699-707.

(84) Shimshoni JA, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J Med Chem 2007;50(25):6419-6427.

(85) Bialer M. Clinical pharmacology of parenteral use of antiepileptic drugs. Epilepsia 2007;48(SUPPL. 8):46-48.

(86) Bialer M. Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia 2007;48(10):1825-1832.

(87) Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6(9):793-804.

(88) Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs 2007;21(9):765-774.

(89) Chien S, Yao C, Mertens A, Verhaeghe T, Solanki B, Doose DR, et al. An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. Epilepsia 2007;48(7):1328-1338.

(90) Mannens GSJ, Hendrickx J, Janssen CGM, Chien S, Van Hoof B, Verhaeghe T, et al. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab Dispos 2007;35(4):554-565.

(91) Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-Da-Silva P. Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48(3):497-504.

(92) Shimshoni JA, Dalton EC, Jenkins A, Eyal S, Ewan K, Williams RSB, et al. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol Pharmacol 2007;71(3):884-892.

(93) Bialer M, Yagen B. Valproic Acid: Second Generation. Neurotherapeutics 2007;4(1):130-137.

(94) Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res 2007;73(1):1-52.

(95) Sobol E, Yagen B, Lamb JG, White HS, Wlodarczyk BJ, Finnell RH, et al. Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide. Epilepsy Res 2007;73(1):75-84.

(96) Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia 2006;47(11):1822-1829.

(97) Chien S, Bialer M, Solanki B, Verhaeghe T, Doose DR, Novak G, et al. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia 2006;47(11):1830-1840.

(98) Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E, Altschuler Y, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol 2006;149(3):250-260.

(99) Sobol E, Yagen B, Steve White H, Wilcox KS, Lamb JG, Pappo O, et al. Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug. Neuropharmacology 2006;51(4):933-946.

(100) Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Invest Drugs 2006;15(6):637-647.

(101) Okada A, Onishi Y, Aoki Y, Yagen B, Sobol E, Bialer M, et al. Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. Birth Defects Res Part B Dev Reprod Toxicol 2006;77(3):227-233.

(102) Bialer M. The pharmacokinetics and interactions of new antiepileptic drugs: An overview. Ther Drug Monit 2005;27(6):722-726.

(103) Winkler I, Blotnik S, Shimshoni J, Yagen B, Devor M, Bialer M. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br J Pharmacol 2005;146(2):198-208.

(104) Winkler I, Sobol E, Yagen B, Steinman A, Devor M, Bialer M. Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain. Neuropharmacology 2005;49(8):1110-1120.

(105) Sobol E, Yagen B, Winkler I, Britzi M, Gibson D, Bialer M. Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats. Drug Metab Dispos 2005;33(10):1538-1546.

(106) Mimrod D, Specchio LM, Britzi M, Perucca E, Specchio N, Neve AL, et al. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia 2005;46(7):1046-1054.

(107) Eyal S, Yagen B, Shimshoni J, Bialer M. Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem Pharmacol 2005;69(10):1501-1508.

(108) Okada A, Kushima K, Aoki Y, Bialer M, Fujiwara M. Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. Birth Defects Res Part A Clin Mol Teratol 2005;73(4):229-238.

(109) Sobol E, Bialer M. Critical analysis of the discrepancy between Vβ and Vss for drugs exhibiting different two-compartment disposition profiles. Biopharm Drug Dispos 2005;26(2):51-58.

(110) Britzi M, Perucca E, Soback S, Levy RH, Fattore C, Crema F, et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 2005;46(3):378-384.

(111) Bialer M. Interactions of antiepileptic drugs. Zh Nevrol Psikhiatr Im S S Korsakova 2005;105(9):59-60.

(112) Shank RP, Doose DR, Streeter AJ, Bialer M. Plasma and whole blood pharmacokinetics of topiramate: The role of carbonic anhydrase. Epilepsy Res 2005;63(2-3):103-112.

(113) Bialer M, Twyman RE, White HS. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 2004;5(6):866-872.

(114) Shaltiel G, Shamir A, Shapiro J, Ding D, Dalton E, Bialer M, et al. Valproate decreases inositol biosynthesis. Biol Psychiatry 2004;56(11):868-874.

(115) Okada A, Aoki Y, Kushima K, Kurihara H, Bialer M, Fujiwara M. Polycomb homologs are involved in teratogenicity of valproic acid in mice. Birth Defects Res Part A Clin Mol Teratol 2004;70(11):870-879.

(116) Bialer M, Doose DR, Murthy B, Curtin C, Wang S-, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;43(12):763-780.

(117) Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004;61(1-3):1-48.

(118) Sobol E, Bialer M, Yagen B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J Med Chem 2004;47(17):4316-4326.

(119) Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004;45(7):737-744.

(120) Sobol E, Bialer M. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model. Biopharm Drug Dispos 2004;25(4):157-162.

(121) Gil-Nagel A, Perucca E, García-Morales I, Arroyo S, Serratosa JM, Avanzini G, et al. Evaluations and Awards at the Fifth European Congress of Epileptology, Madrid, 6-10 October 2002. Epilepsia 2004;45(4):396-398.

(122) Sobol E, Bialer M. Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (VSS) utilizing model-indepent approach. Biopharm Drug Dispos 2004;25(2):99-101.

(123) Okada A, Kurihara H, Aoki Y, Bialer M, Fujiwara M. Amidic Modification of Valproic Acid Reduces Skeletal Teratogenicity in Mice. Birth Defects Res Part B Dev Reprod Toxicol 2004;71(1):47-53.

(124) Isoherranen N, Levy RH, Yagen B, Woodhead JH, White HS, Bialer M. Metabolism of a new antiepileptic drug, N-methyl- tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites. Epilepsy Res 2004;58(1):1-12.

(125) Isoherranen N, Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, et al. Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2-Pyrrolidinone N-Butyric Acid, and Its Enantiomer (R)-α -ethyl-oxo-pyrrolidine Acetamide in a Mouse Model of Teratogenicity. Epilepsia 2003;44(10):1280-1288.

(126) Isoherranen N, White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, et al. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharm Res 2003;20(8):1293-1301.

(127) Doose DR, Brodie MJ, Wilson EA, Chadwick D, Oxbury J, Berry DJ, et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia 2003;44(7):917-922.

(128) Johannessen SI, Battino D, Berry DJ, Bialer M, Krämer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003;25(3):347-363.

(129) Britzi M, Soback S, Isoherranen N, Levy RH, Perucca E, Doose DR, et al. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit 2003;25(3):314-322.

(130) Isoherranen N, Yagen B, Spiegelstein O, Finnell RH, Merriweather M, Woodhead JH, et al. Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. Br J Pharmacol 2003;139(4):755-764.

(131) Isoherranen N, Yagen B, Spiegelstein O, Steinman A, Finnell RH, Bialer M. Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma. J Chromatogr B Biomed Anal Technol Biomed Life Sc 2003;788(1):125-136.

(132) Isoherranen N, Yagen B, Bialer M. New CNS-active drugs which are second-generation valproic acid: Can they lead to the development of a magic bullet? Curr Opin Neurol 2003;16(2):203-211.

(133) Isoherranen N, Yagen B, Woodhead JH, Spiegelstein O, Blotnik S, Wilcox KS, et al. Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. Br J Pharmacol 2003;138(4):602-613.

(134) Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 2003;44(4):540-549.

(135) Williams J, Bialer M, Johannessen SI, Krämer G, Levy R, Mattson RH, et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia 2003;44(1):40-45.

(136) Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, et al. Erratum: Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients (Epilepsia (2002) 43 (691-696)). Epilepsia 2002;43(10):1273.

(137) Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51(1-2):31-71.

(138) Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002;43(7):691-696.

(139) Isoherranen N, White HS, Finnell RH, Yagen B, Woodhead JH, Bennett GD, et al. Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: A new antiepileptic drug. Epilepsia 2002;43(2):115-126.

(140) Bialer M. New antiepileptic drugs currently in clinical trials: Is there a strategy in their development? Ther Drug Monit 2002;24(1):85-90.

(141) Bialer M, Walker MC, Sander JW. Pros and cons for the development of new antiepileptic drugs. CNS Drugs 2002;16(5):285-289.

(142) Isherranen N, Woodhead JH, Steve White H, Bialer M. Anticonvulsant profile of valrocemide (TV1901): A new antiepileptic drug. Epilepsia 2001;42(7):831-836.

(143) Isoherranen N, Yagen B, Soback S, Roeder M, Schurig V, Bialer M. Pharmacokinetics of levetiracetam and its enantiomer (R)-α-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 2001;42(7):825-830.

(144) Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001;43(1):11-58.

(145) Wasserman M, Yagen B, Blotnik S, Papo N, Bialer M. Stereoselective pharmacokinetic analysis and antiepileptic activity of n-2-hydroxypropyl valpromide, a central nervous system-active chiral valproylamide. Ther Drug Monit 2001;23(4):414-420.

(146) Spiegelstein O, Yagen B, Bennett GD, Finnell RH, Blotnik S, Bialer M. Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. Ther Drug Monit 2000;22(5):574-581.

(147) Britzi M, Bialer M, Arcavi L, Shachbari A, Kapitulnik J, Soback S. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Ther Drug Monit 2000;22(5):510-516.

(148) Isoherranen N, Roeder M, Soback S, Yagen B, Schurig V, Bialer M. Enantioselective analysis of levetiracetam and its enantiomer R-α- ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. J Chromatogr B Biomed Sci Appl 2000;745(2):325-332.

(149) Spiegelstein O, Kroetz DL, Levy RH, Yagen B, Hurst SI, Levi M, et al. Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid. Pharm Res 2000;17(2):216-221.

(150) Volosov A, Bialer M, Xiaodong S, Perucca E, Sintov A, Yagen B. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine- 10,11-trans-dihydrodiol in human urine. J Chromatogr B Biomed Sci Appl 2000;738(2):419-425.

(151) Volosov A, Yagen B, Bialer M. Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs. Epilepsia 2000;41(9):1107-1111.

(152) Lindekens H, Smolders I, Khan GM, Bialer M, Ebinger G, Michotte Y. In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy. Pharm Res 2000;17(11):1408-1413.

(153) Spiegelstein O, Yagen B, Levy RH, Finnell RH, Bennett GD, Roeder M, et al. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm Res 1999;16(10):1582-1588.

(154) Bialer M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J Control Release 1999;62(1-2):187-192.

(155) Spiegelstein O, Bialer M, Radatz M, Nau H, Yagen B. Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid. Chirality 1999;11(8):645-650.

(156) Volosov A, Sintov A, Bialer M. Stereoselective pharmacokinetic analysis of the antiepileptic 10- hydroxycarbazepine in dogs. Ther Drug Monit 1999;21(2):219-223.

(157) Sussan S, Dagan A, Blotnik S, Bialer M. The structural requirements for the design of antiepileptic-glycine derivatives. Epilepsy Res 1999;34(2-3):207-220.

(158) Roeder M, Spiegelstein O, Schurig V, Bialer M, Yagen B. Absolute configuration of the four stereoisomers of valnoctamide (2- ethyl-3-methyl valeramide), a potentially new stereospecific antiepileptic and CNS drug. Tetrahedron Asymmetry 1999;10(5):841-853.

(159) Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of The Fourth Eilat Conference (EILAT IV). Epilepsy Res 1999;34(1):1-41.

(160) Volosov A, Bialer M. Use of mean residence time to determine the magnitude of difference between rate constants and to calculate t(max) in the Bateman equation. Biopharm Drug Dispos 1999;20(1):3-9.

(161) Sussan S, Dagan A, Bialer M. Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives. Epilepsy Res 1999;33(1):11-21.

(162) Spiegelstein O, Yagen B, Bialer M. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Epilepsia 1999;40(5):545-552.

(163) Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999;66(6):547-553.

(164) Bialer M, Arcavi L, Sussan S, Volosov A, Yacobi A, Moros D, et al. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Epilepsy Res 1998;32(3):371-378.

(165) Bialer M, Yacobi A, Moros D, Levitt B, Houle J-, Munsaka MS. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 1998;39(5):513-519.

(166) Blotnik S, Bergman F, Bialer M. Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. Eur J Pharm Sci 1998;6(2):93-98.

(167) Radatz M, Ehlers K, Yagen B, Bialer M, Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998;30(1):41-48.

(168) Bialer M, Levy RH, Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit 1998;20(1):56-59.

(169) Hadad S, Bialer M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm Drug Dispos 1997;18(7):557-566.

(170) Spiegelstein O, Bialer M, Yagen B. Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography. J CHROMATOGR B BIOMED APPL 1997;698(1-2):195-200.

(171) Blotnik S, Bergman F, Bialer M. The disposition of valproyl glycinamide and valproyl glycine in rats. Pharm Res 1997;14(7):873-878.

(172) Levi M, Yagen B, Bialer M. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives. Pharm Res 1997;14(2):213-217.

(173) Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Erratum: Corrigendum to: 'Conference report. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference' [Epilepsy Res. 25 (1996) 299] (S0920121196000812). Epilepsy Res 1997;26(3):465.

(174) Barel S, Yagen B, Schurig V, Soback S, Pisani F, Perucca E, et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin Pharmacol Ther 1997;61(4):442-449.

(175) Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference. Epilepsy Res 1996;25(3):299-319.

(176) Bialer M, Kadry B, Abdul-Hai A, Haj-Yehia A, Sterling J, Herzig Y, et al. Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. Biopharm Drug Dispos 1996;17(7):565-575.

(177) Blotnik S, Bergman F, Bialer M. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Drug Metab Dispos 1996;24(5):560-564.

(178) Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996;31(1):29-46.

(179) Bialer M, Hadad S, Kadry B, Abdul-Hai A, Haj-Yehia A, Sterling J, et al. Pharmacokinetic Analysis and Antiepileptic Activity of Tetra-Methylcyclopropane Analogues of Valpromide. Pharm Res 1996;13(2):284-289.

(180) Hadad S, Bialer M. Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine. Pharm Res 1995;12(6):905-910.

(181) Samara E, Avnir D, Ladkani D, Bialer M. Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. Biopharm Drug Dispos 1995;16(3):201-210.

(182) Bialer M, Sussan S, Salach OA, Danenberg HD, Ben‐David J, Gibor Y, et al. Criteria to assess in vivo performance of sustained release products: Application to diltiazem formulations. J Pharm Sci 1995;84(10):1160-1163.

(183) Stables JP, Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, et al. Progress report on new antiepileptic drugs A summary of the Second Eilat Conference. Epilepsy Res 1995;22(3):235-246.

(184) Barel S, Yagen B, Bialer M. Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs. Biopharm Drug Dispos 1994;15(7):609-616.

(185) Bialer M, Haj-Yehia A, Badir K, Hadad S. Can we develop improved derivatives of valproic acid? Pharm World Sci 1994;16(1):2-6.

(186) Soback S, Gips M, Bialer M, Bor A. Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. Antimicrob Agents Chemother 1994;38(10):2336-2339.

(187) Abu Salach O, Hadad S, Haj-Yehia A, Sussan S, Bialer M. FC27 comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity. Eur J Pharm Sci 1994;2(1-2):107.

(188) Salach OA, Hadad S, Haj-Yehia A, Sussan S, Bialer M. Comparative Pharmacokinetic and Pharmacodynamic Analysis of Phthaloyl Glycine Derivatives with Potential Antiepileptic Activity. Pharm Res 1994;11(10):1429-1434.

(189) Bialer M, Pharaj Z, Zuckerman S, Raz I, Abramsky O, Sterling J, et al. Pharmacokinetic analysis of valdice - a diethylcarbonate prodrug of valproic acid. Eur J Pharm Sci 1994;2(3):239-244.

(190) Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, et al. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56(5):471-476.

(191) Bialer M, Hadad S, Golomb G, Barel S, Samara E, Salach OA, et al. Pharmacokinetic analysis of two new sustained‐release products of diltiazem designed for twice‐and once‐daily treatment. Biopharm Drug Dispos 1994;15(1):45-52.

(192) Pisani F, Haj-Yehia A, Fazio A, Artesi C, Oteri G, Perucca E, et al. Interaction of Carbamazepine with Valnoctamide: Data 'in vitro' and in patients with epilepsy. BOLL LEGA ITAL EPILESSIA 1993(82-83):159.

(193) Bialer M. Comparative Pharmacokinetics of the Newer Antiepileptic Drugs. Clin Pharmacokinet 1993;24(6):441-452.

(194) Yagen B, Bialer M. Metabolism and pharmacokinetics of t-2 toxin and related trichothecenes. Drug Metab Rev 1993;25(3):281-323.

(195) Gabizon AA, Barenholz Y, Bialer M. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs. Pharm Res 1993;10(5):703-708.

(196) Hadad S, Vree TB, Van Der Kleijn E, Bialer M. Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid. Biopharm Drug Dispos 1993;14(1):51-59.

(197) Bialer M. Pharmacokinetic Evaluation of Sustained Release Formulations of Antiepileptic Drugs: Clinical Implications. Clin Pharmacokinet 1992;22(1):11-21.

(198) Haj-Yehia A, Hadad S, Bialer M. Pharmacokinetic Analysis of the Structural Requirements for Forming “Stable” Analogues of Valpromide. Pharm Res 1992;9(8):1058-1063.

(199) Hadad S, Vree TB, Kleijn EVD, Bialer M. Pharmacokinetic analysis of ester prodrugs of valproic acid. J Pharm Sci 1992;81(10):1047-1050.

(200) Samara E, Bialer M, Harvey DJ. Metabolism of cannabidiol by the rat. Eur J Drug Metab Pharmacokinet 1991;16(4):305-313.

(201) Bialer M. Clinical Pharmacology of Valpromide. Clin Pharmacokinet 1991;20(2):114-122.

(202) Badir K, Haj-Yehia A, Vree TB, van der Kleijn E, Bialer M. Pharmacokinetics and Anticonvulsant Activity of Three Monoesteric Prodrugs of Valproic Acid. Pharm Res 1991;8(6):750-753.

(203) McLean AM, Cefali EA, Roden JS, Gonzalez MA, Bialer M. Stability of diltiazem in different biological fluids. Biopharm Drug Dispos 1991;12(5):327-334.

(204) Betlach CJ, Straughn AB, Meyer MC, Bialer M, Vashi VI, Lieberman P, et al. The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet. Pharm Res 1991;8(12):1516-1519.

(205) Samara E, Bialer M, Harvey DJ. Identification of urinary metabolites of cannabidiol in the dog. Drug Metab Dispos 1990;18(5):571-579.

(206) Billig H, Ziv E, Bar-on H, Bialer M. The disposition of valpromide in rats and the isolated perfused rat liver. Drug Metab Dispos 1990;18(2):238-244.

(207) Bialer M, Haj-Yehia A, Barzaghi N, Pisani F, Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur J Clin Pharmacol 1990;38(3):289-291.

(208) Haj‐Yehia A, Bialer M. Structure–pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J Pharm Sci 1990;79(8):719-724.

(209) Samara E, Bialer M, Harvey DJ. Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharm Drug Dispos 1990;11(9):785-795.

(210) Barel S, Yagen B, Bialer M. Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs. J Pharm Sci 1990;79(6):548-551.

(211) Samara E, Bialer M, Harvey DJ. Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog. Xenobiotica 1990;20(2):177-183.

(212) Samara E, Bialer M, Bar-On H, Harvey DJ. Identification of metabolites of the 1'1'dimethylheptyl analogue of cannabidiol in rat and dog in viv. Xenobiotica 1990;20(5):447-455.

(213) McLean AM, Ruggirello DA, Banfield C, Gonzalez MA, Bialer M. Application of a variance‐stabilizing transformation approach to linear regression of calibration lines. J Pharm Sci 1990;79(11):1005-1008.

(214) Haj-Yehia A, Bialer M. Structure–Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity. Pharm Res 1989;6(8):683-689.

(215) David JB, Bialer M. Pharmacokinetic interaction between diltiazem and amiodarone in the dog. Biopharm Drug Dispos 1989;10(4):423-429.

(216) Mason EJ, Bialer M. The logical structure and validity of experimental designs in pharmacokinetics and clinical pharmacology. Biopharm Drug Dispos 1989;10(4):331-351.

(217) Samara E, Bialer M. Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs. Drug Metab Dispos 1988;16(6):875-879.

(218) Haj‐Yehia A, Bialer M. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J Pharm Sci 1988;77(10):831-834.

(219) Sintov A, Bialer M, Yagen B. Pharmacokinetics and protein binding of trichothecene mycotoxins, T-2 toxin and HT-2 toxin, in dogs. Toxicon 1988;26(2):153-160.

(220) Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 1988;16(3):469-472.

(221) Maislos M, Bialer M, Mead PM, Robbins DC. Pharmacokinetic model of circulating covalent aggregates of insulin. Diabetes 1988;37(8):1059-1063.

(222) Bialer M, Wu WH, Faulkner RD, Michael Silber B, Yacobi A. In vitro protein binding interaction studies involving cefixime. Biopharm Drug Dispos 1988;9(3):315-320.

(223) Bialer M, Wu WH, Look ZM, Silber BM, Yacobi A. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: Bioavailability assessment for a drug showing nonlinear serum protein binding. Res Commun Chem Pathol Pharmacol 1987;56(1):21-32.

(224) Samara E, Bialer M. Rapid high-performance liquid chromatographic assay with pharmacokinetic applications for monitoring cannabidiol in plasma. J Chromatogr B Biomed Sci Appl 1987;416(C):370-374.

(225) Sintov A, Bialer M, Yagen B. Pharmacokinetics of t-2 tetraol, a urinary metabolite of the trichothecene mycotoxin, t-2 toxin, in dog. Xenobiotica 1987;17(8):941-950.

(226) Hussein Z, Bialer M, Friedman M, Raz I. Pharmacokinetic analysis of sustained‐release dosage forms of theophylline in humans: Comparison of single and multiple dose studies. Biopharm Drug Dispos 1987;8(5):427-435.

(227) Hussein Z, Bialer M, Friedman M, Raz I. Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans. Int J Pharm 1987;37(1-2):97-102.

(228) Bialer M, Batra VK, Morrison JA, Silber BM, Look ZM, Yacobi A. Dose-Dependent Pharmacokinetics of a New Oral Cephalosporin, Cefixime, in the Dog. Pharm Res 1987;4(1):33-37.

(229) Pei Y‐, Bialer M, Levy RH. Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat. Biopharm Drug Dispos 1986;7(1):11-19.

(230) Sintov A, Bialer M, Yagen B. Pharmacokinetics of T-2 toxin and its metabolite HT-2 toxin, after intravenous adminstration in dogs. Drug Metab Dispos 1986;14(2):250-254.

(231) Bialer M, Friedman M, Dubrovsky J. Relation between absorption half‐life values of four novel sustained‐release dosage forms of valproic acid in dogs and human. Biopharm Drug Dispos 1986;7(5):495-500.

(232) Yagen B, Sintov A, Bialer M. New, sensitive thin-layer chromatographic-high-performance liquid chromatographic method for detection of trichothecene mycotoxins. J Chromatogr A 1986;356(C):195-201.

(233) Bialer M, Look ZM, Silber BM, Yacobi A. The relationship between drug input and mean residence time in the body. Biopharm Drug Dispos 1986;7(6):577-583.

(234) Bialer M, Tonelli AP, Kantrowitz JD, Yacobi A. Serum protein binding of a new oral cephalosporin, CL 284,635, in various species. Drug Metab Dispos 1986;14(1):132-136.

(235) Tonelli AP, Bialer M, Look ZM, Carson S, Yacobi A. Saturable Processes Affecting Renal Clearance of Cefixime in Dogs. Pharm Res 1986;3(3):150-155.

(236) Rubinstein A, Bialer M, Friedman M, Raz I, Abramsky O. A combined approach to control valproic acid release via novel delivery system of valpromide: A kinetic and pharmacokinetic study. J Control Release 1986;4(1):33-38.

(237) Bialer M, Salame K, Raz I. Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1985;23(12):662-667.

(238) Bialer M, Hoch B. Rapid gas chromatographic assay for monitoring valnoctamide in plasma. J Chromatogr B Biomed Sci Appl 1985;337(C):408-411.

(239) Tonelli AP, Bialer M, Yacobi A. Relationship between protein binding and renal clearance of a new oral cephalosporin in the dog. J Pharm Sci 1985;74(11):1242-1244.

(240) Yagen B, Bialer M, Sintov A. Gas chromatographic assay with pharmacokinetic applications for monitoring T-2 and HT-2 toxins in plasma. J Chromatogr B Biomed Sci Appl 1985;343(C):67-75.

(241) Bialer M, Friedman M, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetic evaluation of novel sustained‐release dosage forms of valproic acid in humans. Biopharm Drug Dispos 1985;6(4):401-411.

(242) Bialer M, Rubinstein A, Dubrovsky J, Raz I, Abramsky O. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. Int J Pharm 1985;23(1):25-33.

(243) Bialer M, Hussein Z, Raz I, Abramsky O, Herishanu Y, Pachys F. Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharm Drug Dispos 1985;6(1):33-42.

(244) Bialer M, Hussein Z, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. Isr J Med Sci 1984;20(1):46-49.

(245) Bialer M, Rubinstein A, Raz I, Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol 1984;27(4):501-503.

(246) Raz I, Bialer M, Salame K, Bar-On H. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans. Eur J Clin Pharmacol 1984;26(3):401-403.

(247) Bialer M, Rubinstein A. Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharm Drug Dispos 1984;5(2):177-183.

(248) Bialer M, Friedman M, Dubrovsky J. Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs. Biopharm Drug Dispos 1984;5(1):1-10.

(249) Bialer M, Friedman M, Dubrovsky J. Effect of sustained release on the pharmacokinetics of valproic acid in the dog. Int J Pharm 1984;20(1-2):53-63.

(250) Bialer M, Friedman M, Rubinstein A. Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma. J Pharm Sci 1984;73(7):991-993.

(251) Bialer M, Sloneker SD, Kostenbauder HB. Isolation of a cigarette smoke fraction responsible for the inhibition of benzo[a]pyrene metabolism in the isolated perfused rabbit lung. Chem -Biol Interact 1984;51(3):309-320.

(252) Johno I, Bialer M, Nickelson SA, Levy RH. Disposition of Progabide and Valproic Acid Following Intraperitoneal Administration in Rhesus Monkey. Epilepsia 1984;25(5):578-585.

(253) Bialer M. Estimation of pharmacokinetic parameters in extravascular multiple dose administration in the one-compartment open body model with equal absorption and elimination first-order rate constants. Int J Pharm 1983;13(3):345-348.

(254) Bialer M, Rubinstein A. A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs. J Pharm Pharmacol 1983;35(9):607-609.

(255) Bialer M, Hussein Z, Herishanu Y, Melnik Y. An alternative method for calculating absorption and elimination rate constants in first-order processes: application to valproic acid. Int J Pharm 1983;16(3):285-294.

(256) Garrett ER, Green JR, Bialer M. Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. Biopharm Drug Dispos 1982;3(2):129-164.

(257) Bialer M. An unusual cleavage of ring D in Δ14-17-keto steroid after a reaction with alkaline hydrogen peroxide. Tetrahedron Lett 1981;22(28):2683-2684.

(258) Bialer M. An alternative method for calculating simple pharmacokinetic parameters for zero‐order absorption and first‐order elimination processes. Biopharm Drug Dispos 1981;2(4):323-327.

(259) Bialer M, El‐On J, Yagen B, Mechoulam R. Antiparasitic structure‐activity relationships of congocidine derivatives. J Pharm Sci 1981;70(7):822-824.

(260) Bourne DWA, Bialer M, Dittert LW, Hayashi M, Rudawsky G, Koritz GD, et al. Disposition of sulfadimethoxine in cattle: Inclusion of protein binding factors in a pharmacokinetic model. J Pharm Sci 1981;70(9):1068-1072.

(261) Bialer M, Yagen B, Mechoulam R, Becker Y. Structure-Activity Relationships of Pyrrole Amidine Antiviral Antibiotics. 2. Preparation of Mono-and Tripyrrole Derivatives of Congocidine. J Med Chem 1980;23(10):1144-1148.

(262) Bialer M. A simple method for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes. J Pharmacokinet Biopharm 1980;8(1):111-113.

(263) Bialer M, Yagen B, Mechoulam R. Structure elucidation of a condensation product of 4‐aminopyrrole derivatives and dicyclohexylcarbodiimide. J Heterocycl Chem 1980;17(8):1797-1798.

(264) Bialer M, Yagen B, Mechoulam R, Becker Y. Structure–activity relationships of pyrrole amidine antiviral antibiotics III: Preparation of distamycin and congocidine derivatives based on 2,5‐disubstituted pyrroles. J Pharm Sci 1980;69(11):1334-1338.

(265) Bialer M, Yagen B, Mechoulam R, Becker Y. Structure-Activity Relationships of Pyrrole Amidine Antiviral Antibiotics. 1. Modifications of the Alkylamidine Side Chain. J Med Chem 1979;22(11):1296-1301.

(266) Bialer M, Yagen B, Mechoulam R. A total synthesis of distamycin a, an antiviral antibiotic. Tetrahedron 1978;34(15):2389-2391.